Lin, David http://orcid.org/0000-0002-9236-8405
Klein, Allan
Cella, David http://orcid.org/0000-0002-9881-4541
Beutler, Anna http://orcid.org/0000-0001-9660-5394
Fang, Fang http://orcid.org/0000-0001-7625-3408
Magestro, Matt http://orcid.org/0000-0002-2898-3657
Cremer, Paul
LeWinter, Martin M. http://orcid.org/0000-0003-3938-3531
Luis, Sushil Allen http://orcid.org/0000-0001-9821-1225
Abbate, Antonio http://orcid.org/0000-0002-1930-785X
Ertel, Andrew
Litcher-Kelly, Leighann http://orcid.org/0000-0001-9005-6582
Klooster, Brittany http://orcid.org/0000-0002-2018-8982
Paolini, John F. http://orcid.org/0000-0001-7622-8851
Clinical trials referenced in this document:
Documents that mention this clinical trial
Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept
https://doi.org/10.1186/s12872-021-02008-3
Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial
https://doi.org/10.1136/heartjnl-2020-317928
Funding for this research was provided by:
Kiniksa Pharmaceuticals, Ltd.
Article History
Received: 4 February 2021
Accepted: 12 April 2021
First Online: 21 April 2021
Declarations
:
: Ethics approval for the qualitative interviews was granted by Sterling IRB under IRB ID# 6406. Ethics approval for the Phase 2 study was granted by the central IRB Aspire under IRB ID# KPL-914-C001 as well as by site-specific central and local IRBs, including Chesapeake IRB, Cleveland Clinic Foundation IRB, Mayo Clinic IRB, University of Vermont Research Protections Office Committee on Human Research in the Medical Sciences, and Western IRB.
: Not applicable.
: David Lin: None. Allan Klein: Research grant, scientific advisory board Kiniksa Pharmaceuticals, Ltd., advisory board Swedish Orphan Biovitrum AB, advisory board Pfizer, Inc., modest. David Cella: Consultant for Kiniksa Pharmaceuticals, Ltd., modest. Anna Beutler: Kiniksa Pharmaceuticals, Ltd. consultant. Fang Fang: Kiniksa Pharmaceuticals, Corp. employee. Matt Magestro: Kiniksa Pharmaceuticals, Corp. employee. Paul Cremer: Advisory board Swedish Orphan Biovitrum AB, advisory board Kiniksa Pharmaceuticals, Ltd., modest. Martin M. LeWinter: One seminar for Kiniksa Pharmaceuticals, Ltd., modest. Sushil Allen Luis: Advisory board member for Kiniksa Pharmaceuticals, Ltd., modest. Consultant and advisory board member for Swedish Orphan Biovitrum AB, significant. Antonio Abbate: Research grants from Kiniksa Pharmaceuticals, Ltd., Swedish Orphan Biovitrum AB, Olatec Therapeutics LLC, Serpin Pharma, LLC; consultant fees: Kiniksa Pharmaceuticals, Ltd., Olatec Therapeutics LLC, Serpin Pharma, LLC, Merck & Co., Inc., modest. Andrew Ertel: None. Leighann Litcher-Kelly: Employed by Adelphi Values, which received funding from Kiniksa Pharmaceuticals, Ltd. for PRO work in pericarditis. Brittany Klooster: Employed by Adelphi Values, which received funding from Kiniksa Pharmaceuticals, Ltd. for PRO work in pericarditis. John F. Paolini: Kiniksa Pharmaceuticals, Corp. Employee.